In a groundbreaking stride towards revolutionising cancer treatment, Tempus, a Chicago-based technology company specializing in artificial intelligence and precision medicine, is set to present an array of research findings at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, from April 5-10. The company has announced that a total of 18 abstracts, highlighting innovative uses of its AI-enabled precision medicine platform in cancer research, have been accepted for presentation.

Tempus, known for its dedication to advancing precision medicine through the application of AI, operates on the frontier of healthcare and technology. Its mission to make the vast ocean of multimodal data available and operational stands as a testament to its pioneering approach in the realm of personalized patient care and therapeutic discovery and delivery. With one of the world’s largest databases of its kind, Tempus is not only transforming how physicians approach cancer treatment but is also paving the way for more tailored therapeutics to reach patients more effectively.

One of the standout pieces of research to be presented involves the use of Tempus’ xM algorithm for treatment response monitoring (TRM) in metastatic breast cancer patients. The xM TRM algorithm, adept at quantifying changes in circulating DNA tumor fractions and detecting ESR1 mutations — a marker associated with resistance to aromatase inhibitors — has shown promising correlations with overall survival outcomes. This pioneering research offers new avenues for monitoring treatment responses and could significantly impact the decision-making process in switching therapies for patients exhibiting poor response on current treatments.

Another significant area of Tempus’ research delves into the detection of clonal hematopoiesis (CH) from tumor-derived variants in liquid biopsy samples. Through the training of a sophisticated random forest classifier, the Tempus team has developed a method with the potential to accurately distinguish between CH and tumor variants solely based on liquid biopsy data. This innovation stands to streamline and simplify diagnostic approaches, reducing reliance on more complex combined liquid and solid-based methodologies.

Tempus is also presenting findings from its study on the association of circulating tumor DNA (ctDNA) biomarkers with clinical outcomes in patients treated with Tyrosine kinase inhibitors (TKIs) across various cancer types. The research demonstrates that molecular responders, as determined by significant reductions in ctDNA tumor fractions, exhibit notably improved survival outcomes. These insights could dramatically change how treatments are chosen and applied, sparing patients from undergoing ineffective therapies.

The AACR Annual Meeting serves as a grand stage for Tempus to not only showcase its contributions to the field of oncology but also to emphasize the incredible potential of AI and multimodal data in fostering more personalized and effective cancer treatments. The breadth and depth of the research to be presented underline Tempus’s unwavering commitment to leveraging technology in the continuous fight against cancer.

Tempus’s presence at the AACR Annual Meeting underscores an exciting era of innovation in healthcare, where data and technology converge to offer real hope and more precise solutions for patients navigating the complexities of cancer treatment. As the company continues to expand its library of multimodal data and refine its AI-enabled solutions, the vision of delivering personalized patient care is increasingly becoming a palpable reality, promising a brighter future for cancer patients around the globe.